Mounjaro Uk

Mounjaro Uk

Mounjaro UK is a prescription medication with the active ingredient tirzepatide, used to treat adults with type 2 diabetes and for chronic weight management. It is administered as a once-weekly subcutaneous injection. 
Mounjaro Uk
Mounjaro Uk
Mounjaro Uk
Mounjaro Uk
Key Information
    • Active Ingredient: Tirzepatide.
    • Drug Class: It is a dual agonist that mimics two natural gut hormones: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
    • Indications:
        • Type 2 Diabetes: Used alongside diet and exercise to improve blood sugar (glycemic) control.
    • Weight Management: Approved for adults with obesity (BMI of 30 kg/m² or greater) or who are overweight (BMI between 27 and 30 kg/m²) and have a weight-related health condition (e.g., high blood pressure, high cholesterol, type 2 diabetes).
  • Administration: A once-weekly self-injection using a pre-filled pen (KwikPen) into the abdomen, thigh, or upper arm. The injection site should be rotated each week.
How It Works
Mounjaro’s dual action on both GIP and GLP-1 receptors helps to: 
  • Increase insulin secretion from the pancreas in response to food.
  • Reduce the amount of sugar the liver produces.
  • Slow down stomach emptying, which makes you feel fuller for longer.
  • Reduce appetite and cravings. 
This unique dual mechanism is associated with greater weight loss compared to medications that target only the GLP-1 receptor, such as Ozempic or Wegovy. 
Common Side Effects
Most side effects are gastrointestinal in nature and tend to be mild to moderate, often occurring when starting treatment or increasing the dose: 
  • Nausea (feeling sick)
  • Diarrhea
  • Decreased appetite
  • Constipation
  • Vomiting
  • Stomach pain 
Important Considerations and Warnings
  • Prescription Only: Mounjaro is a prescription-only medicine and requires a consultation with a healthcare provider to ensure it is safe and appropriate for you.
  • Lifestyle Changes: It is intended for use as an adjunct to a reduced-calorie diet and increased physical activity for best results.
  • Thyroid Tumors: In rodent studies, Mounjaro and similar medicines caused thyroid C-cell tumors. It is unknown if this occurs in humans. It should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Contraception: Mounjaro can reduce the effectiveness of oral birth control pills due to delayed gastric emptying. Women using oral contraceptives should switch to a non-oral method or add a barrier method for four weeks after starting Mounjaro and after each dose escalation.
  • Zepbound: The same active ingredient, tirzepatide, is marketed under the brand name Zepbound specifically for chronic weight management in the U.S., while Mounjaro is approved for type 2 diabetes.